Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytokine-induced killer cells (bff2a8)
- Development stage
- Unknown
- Lead developer
- Yanjuan Zhu
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cytokine-induced killer (CIK) cells are an autologous, ex vivo-expanded population of immune effector cells, primarily characterized by a CD3+CD56+ phenotype. They are generated from a patient's peripheral blood mononuclear cells (PBMCs) through stimulation with interferon-gamma (IFN-γ), interleukin-2 (IL-2), and anti-CD3 antibodies. This cell therapy combines the potent anti-tumor activity of T cells with the non-MHC-restricted cytotoxicity of natural killer (NK) cells. In the context of colon cancer, specifically stage II/III, CIK cells are investigated as an adjuvant immunotherapy following surgical resection and chemotherapy to eliminate residual micrometastases and reduce recurrence rates. The therapy was notably studied in a Phase 2 clinical trial (NCT01800058) led by Yanjuan Zhu, which evaluated the efficacy of CIK cell transfusion in prolonging disease-free survival and overall survival.
- Other names
- CIK cellsautologous cytokine-induced killer cellsadjuvant CIK immunotherapy
02
Targets
FASN (Fatty acid synthase)FCGR3B (Fc gamma receptor III)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on cytokine-induced killer cells (bff2a8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytokine-induced killer cells (bff2a8).